Choosing a Local Comparator for MedTech Reimbursement Dossiers in Brazil, Colombia, and Mexico

For a MedTech company entering Latin America, the local comparator is more than a line in a clinical-evidence table. It is the reference point that lets a payer, hospital, or health technology assessment (HTA) team judge whether a new device changes outcomes, workflow, resource use, or total cost. A comparator that is scientifically convenient but disconnected from local practice can weaken a reimbursement dossier even when the device performs well.

The right approach is to choose a comparator by country and care pathway, then build a bridge back to the evidence collected during early clinical development. Brazil, Colombia, and Mexico each have distinct institutions and decision contexts. A common evidence core can support all three, but the comparator rationale and resource-use assumptions should be localized.

Why comparator choice determines payer credibility

A comparator should represent the decision a local clinician or purchaser would make if the new technology were not available. That may be an established device, a procedure, a diagnostic pathway, watchful waiting, or a combination of services. The relevant question is not “What is the closest product?” It is “What happens to this patient in this health system today?”

This distinction matters because HTA considers more than technical performance. Brazil’s CONITEC describes technology assessment in terms that include clinical evidence, economic evaluation, and budget impact. Colombia’s IETS defines HTA as a systematic, multidisciplinary examination of effectiveness, safety, and social, economic, and ethical consequences. Mexico’s CENETEC publishes guidance for the economic evaluation of medical devices. These official frameworks point to the same practical lesson: the comparator must make the consequences of adoption measurable.

Brazil: anchor the dossier in SUS practice and budget impact

For a public-system strategy in Brazil, begin by describing the current SUS pathway for the target patient: who provides care, what procedure or technology is used, what resources are consumed, and where delays or complications arise. The comparator should be the realistic alternative within that pathway, not merely the device with the closest engineering specifications.

Build the evidence package around three layers. First, show comparative clinical outcomes that matter to the patient and provider. Second, quantify resource use, including procedure time, staff, consumables, repeat visits, training, maintenance, and downstream events. Third, model the eligible population and adoption scenarios so the decision maker can see the budget effect under conservative and expanded use.

Use the current CONITEC HTA materials and methodological guidance to confirm the applicable submission expectations. For an early-stage sponsor, the immediate goal is not to claim a final cost-effectiveness result from a small FIH study. It is to capture the baseline workflow and resource variables that a later model will need.

Colombia: make the local care pathway explicit

In Colombia, the comparator should reflect how the service is delivered through the relevant network and what the decision maker can actually change. A global standard of care may not be the operational baseline if local hospitals use a different procedure, staffing model, referral pattern, or purchasing arrangement.

Start with a pathway map: entry point, diagnostic work-up, treatment or intervention, follow-up, complications, and referral. For each step, document who performs it, how long it takes, what equipment and supplies are required, and which outcomes are visible to the payer or hospital. Then explain why the selected comparator is the appropriate reference for that pathway.

IETS materials emphasize clinical effectiveness, safety, and the economic and social implications of health technologies. Translate that multidimensional view into a dossier structure: comparative outcomes, adverse events, quality-of-life or functional measures where relevant, staff and infrastructure requirements, and costs that are material to the Colombian setting. The IETS overview of HTA is a useful official reference when defining the scope of the evidence plan.

Mexico: connect the comparator to implementation and economics

For Mexico, a credible comparator must fit the institution and service context in which the device would be adopted. Ask whether the alternative is delivered in public hospitals, private facilities, or both; whether the required equipment is already installed; and whether the new technology changes training, staffing, maintenance, or referral patterns.

Separate acquisition price from total implementation cost. A device can appear inexpensive while requiring new imaging, specialized staff, software, service contracts, or additional visits. Conversely, a higher purchase price may be offset by shorter procedure time or fewer repeat interventions. Record these variables prospectively during early studies so that a later economic model can compare like with like.

Review the Mexican CENETEC guidance for economic evaluation of medical devices and adapt the evidence plan to the intended decision setting. Current institutional requirements should be confirmed before a formal submission, especially when the product will be evaluated by more than one payer or hospital network.

Build one comparator matrix across three countries

A sponsor can reduce rework by maintaining a master comparator matrix with country-specific annexes. Capture at least:

• Clinical baseline: the patient population, indication, current intervention, and relevant outcomes.
• Workflow baseline: procedure steps, care setting, staff time, equipment, and referral pattern.
• Safety baseline: complications, repeat procedures, contraindications, and follow-up burden.
• Economic baseline: acquisition, consumables, personnel, maintenance, admissions, and downstream resource use.
• Adoption baseline: training, infrastructure, procurement, and implementation constraints.
• Decision use: the payer, hospital, or HTA question the comparison is intended to answer.

Do not wait for a pivotal trial to collect these fields. Even a small early-feasibility program can record procedure duration, staff mix, consumables, unplanned visits, technical failures, and patient-reported measures using a prespecified template. Those observations will not replace comparative evidence, but they can reveal which assumptions need validation and which outcomes matter locally.

Frequently asked questions

Should the comparator be the cheapest available option?
No. It should be the realistic alternative used in the target care pathway. The lowest purchase price may not be the lowest-cost or most relevant option after staff time, complications, maintenance, and follow-up are included.

Can one comparator serve Brazil, Colombia, and Mexico?
Sometimes the clinical concept is shared, but the service pathway, staffing, infrastructure, and purchasing context may differ. Use a common evidence core with country-specific comparator definitions and assumptions.

Is comparator planning relevant during an FIH study?
Yes. FIH studies are not designed to prove final reimbursement value, but they can capture baseline workflow, safety, resource use, and patient-centered measures that prevent avoidable evidence gaps later.

A locally credible comparator turns a MedTech dossier from a product description into a decision analysis. By defining the reference pathway early and documenting how it differs across Brazil, Colombia, and Mexico, sponsors can make later regulatory, HTA, and reimbursement conversations more focused and more defensible.